Browsing by Author "Haugen, Mads Haugland"

Now showing items 1-13 of 13

  • The Agaricus blazei-Based Mushroom Extract, Andosan™, Protects against Intestinal Tumorigenesis in the A/J Min/+ Mouse 
    Hetland, Geir; Eide, Dag Markus; Tangen, Jon-Magnus; Haugen, Mads Haugland; Mirlashari, Mohammad Reza; Paulsen, Jan Erik (Journal article / Tidsskriftartikkel / PublishedVersion; Peer reviewed, 2016)
    Background The novel A/J Min/+ mouse, which is a model for human Familial Adenomatous Polyposis (FAP), develops spontaneously multiple adenocarcinomas in the colon as well as in the small intestine. Agaricus blazei Murill ...
  • AXL inhibition improves BRAF-targeted treatment in melanoma 
    Nyakas, Marta Sølvi; Fleten, Karianne Giller; Haugen, Mads Haugland; Engedal, Nikolai; Sveen, Christina; Farstad, Inger Nina; Flørenes, Vivi Ann; Prasmickaite, Lina; Mælandsmo, Gunhild Mari; Vasiliauskaite, Kotryna (Journal article / Tidsskriftartikkel / PublishedVersion; Peer reviewed, 2022)
    Abstract More than half of metastatic melanoma patients receiving standard therapy fail to achieve a long-term survival due to primary and/or acquired resistance. Tumor cell ability to switch from epithelial to a more ...
  • Basal-like breast cancer engages tumor-supportive macrophages via secreted factors induced by extracellular S100A4 
    Prasmickaite, Lina; Tenstad, Ellen; Pettersen, Solveig; Jabeen, Shakila; Egeland, Eivind Valen; Nord, Silje; Pandya, Abhilash D.; Haugen, Mads Haugland; Kristensen, Vessela N.; Børresen-Dale, Anne-Lise; Engebråten, Olav; Mælandsmo, Gunhild Mari (Journal article / Tidsskriftartikkel / PublishedVersion; Peer reviewed, 2018)
  • Breast cancer quantitative proteome and proteogenomic landscape 
    Johansson, Henrik J.; Socciarelli, Fabio; Vacanti, Nathaniel M.; Haugen, Mads Haugland; Zhu, Yafeng; Siavelis, Ioannis; Fernandez-Woodbridge, Alejandro; Aure, Miriam Ragle; Sennblad, Bengt; Vesterlund, Mattias; Branca, Rui M.; Orre, Lukas M.; Huss, Mikael; Fredlund, Erik; Beraki, Else; Garred, Øystein; Boekel, Jorrit; Sauer, Torill; Zhao, Wei; Nord, Silje; Höglander, Elen K.; Jans, Daniel C.; Brismar, Hjalmar; Haukaas, Tonje Husby; Bathen, Tone Frost; Schlichting, Ellen; Naume, Bjørn; Luders, Torben; Borgen, Elin; Kristensen, Vessela N.; Russnes, Hege Elisabeth Giercksky; Lingjærde, Ole Christian; Mills, Gordon B.; Sahlberg, Kristine Kleivi; Børresen-Dale, Anne-Lise; Lehtiö, Janne (Journal article / Tidsskriftartikkel / PublishedVersion; Peer reviewed, 2019)
    In the preceding decades, molecular characterization has revolutionized breast cancer (BC) research and therapeutic approaches. Presented herein, an unbiased analysis of breast tumor proteomes, inclusive of 9995 proteins ...
  • Design, synthesis and biological evaluation of 6‐substituted quinolines derived from cabozantinib as c‐Met inhibitors 
    Lien, Vegard Torp; Pettersen, Solveig; Haugen, Mads Haugland; Olberg, Dag Erlend; Mælandsmo, Gunhild Mari; Klaveness, Jo (Journal article / Tidsskriftartikkel / PublishedVersion; Peer reviewed, 2019)
    Based on the cabozantinib scaffold, novel c‐Met inhibitors were rationalized from the limited knowledge of structure‐activity relationships for the quinoline 6‐position. Emphasis was given to modifications capable of ...
  • EMMPRIN is associated with S100A4 and predicts patient outcome in colorectal cancer 
    Boye, Kjetil; Nesland, Jahn M; Sandstad, Berit; Haugen, Mads Haugland; Mælandsmo, Gunhild; Flatmark, Kjersti (Journal article / Tidsskriftartikkel / PublishedVersion; Peer reviewed, 2012)
    Background: Proteolytic enzymes and their regulators have important biological roles in colorectal cancer by stimulating invasion and metastasis, which makes these factors attractive as potential prognostic biomarkers ...
  • MicroRNA in combination with HER2-targeting drugs reduces breast cancer cell viability in vitro 
    Svartdal, Lisa Gregusson; Aure, Miriam Ragle; Leivonen, Suvi-Katri; Haugen, Mads Haugland; Hongisto, Vesa; Kristensen, Vessela N.; Mælandsmo, Gunhild Mari; Sahlberg, Kristine Kleivi (Journal article / Tidsskriftartikkel / PublishedVersion; Peer reviewed, 2021)
    Abstract HER2-positive (HER2 +) breast cancer patients that do not respond to targeted treatment have a poor prognosis. The effects of targeted treatment on endogenous microRNA (miRNA) expression levels are unclear. We ...
  • miR-101-5p Acts as a Tumor Suppressor in HER2-Positive Breast Cancer Cells and Improves Targeted Therapy 
    Normann, Lisa Svartdal; Haugen, Mads Haugland; Aure, Miriam Ragle; Kristensen, Vessela N.; Mælandsmo, Gunhild Mari; Sahlberg, Kristine Kleivi (Journal article / Tidsskriftartikkel / PublishedVersion; Peer reviewed, 2022)
    Purpose: Human epidermal growth factor receptor 2 positive (HER2+) breast cancers responding poorly to targeted therapy need improved treatment options. miR-101-5p has shown tumor-suppressive properties in multiple cancer ...
  • miRNA expression changes during the course of neoadjuvant bevacizumab and chemotherapy treatment in breast cancer 
    Lindholm, Evita Maria; Aure, Miriam Ragle; Haugen, Mads Haugland; Sahlberg, Kristine Kleivi; Kristensen, Vessela N.; Nebdal, Daniel; Børresen-Dale, Anne-Lise; Lingjærde, Ole Christian; Engebråten, Olav (Journal article / Tidsskriftartikkel / PublishedVersion; Peer reviewed, 2019)
    One of the hallmarks of cancer is sustained angiogenesis. Favorable results have been reported in some breast cancer (BC) patients receiving antiangiogenic therapy with bevacizumab (Bev) in combination with chemotherapy, ...
  • Protein kinase C isozymes associated with relapse free survival in non-small cell lung cancer patients 
    Halvorsen, Ann Rita; Haugen, Mads Haugland; Øjlert, Åsa Kristina; Lund-Iversen, Marius; Jørgensen, Lars Hilmar; Solberg, Steinar; Mælandsmo, Gunhild Mari; Brustugun, Odd Terje; Helland, Åslaug (Journal article / Tidsskriftartikkel / PublishedVersion; Peer reviewed, 2020)
    Introduction Protein expression is deregulated in cancer, and the proteomic changes observed in lung cancer may be a consequence of mutations in essential genes. The purpose of this study was to identify protein expression ...
  • Protein signature predicts response to neoadjuvant treatment with chemotherapy and bevacizumab in HER2-negative breast cancers 
    Haugen, Mads Haugland; Lingjærde, Ole Christian; Hedenfalk, Ingrid; Garred, Øystein; Borgen, Elin; Loman, Niklas; Hatschek, Thomas; Børresen-Dale, Anne-Lise; Naume, Bjørn; Mills, Gordon B.; Mælandsmo, Gunhild Mari; Engebråten, Olav (Journal article / Tidsskriftartikkel / PublishedVersion; Peer reviewed, 2021)
    PURPOSE Antiangiogenic therapy using bevacizumab has proven effective for a number of cancers; however, in breast cancer (BC), there is an unmet need to identify patients who benefit from such treatment. PATIENTS AND ...
  • Stroma-induced phenotypic plasticity offers phenotype-specific targeting to improve melanoma treatment 
    Seip, Kotryna; Jørgensen, Kjetil Nordbø; Albrecht, Marco; Haugen, Mads Haugland; Egeland, Eivind Valen; Lucarelli, Philippe; Engebråten, Olav; Sauter, Thomas; Mælandsmo, Gunhild Mari; Prasmickaite, Lina (Journal article / Tidsskriftartikkel / AcceptedVersion; Peer reviewed, 2018)
    Cancer cells’ phenotypic plasticity, promoted by stromal cells, contributes to intra-tumoral heterogeneity and affects response to therapy. We have disclosed an association between fibroblast-stimulated phenotype switching ...
  • Targeting AXL and the DNA damage response pathway as a novel therapeutic strategy in melanoma 
    Karlsen, Karine Flem; McFadden, Erin; Omar, Nasrin; Haugen, Mads Haugland; Øy, Geir Frode; Ryder, Truls; Gullestad, Hans Petter; Hermann, Robert; Mælandsmo, Gunhild Mari; Flørenes, Vivi Ann (Journal article / Tidsskriftartikkel / AcceptedVersion; Peer reviewed, 2020)
    Receptor tyrosine kinase AXL is found upregulated in various types of cancer, including melanoma, and correlates with an aggressive cancer phenotype, inducing cell proliferation and epithelial-to-mesenchymal transition. ...